Rhenium and technetium complexes that bind to amyloid-β plaques.

Alzheimer's disease is associated with the presence of insoluble protein deposits in the brain called amyloid plaques. The major constituent of these deposits is aggregated amyloid-β peptide. Technetium-99m complexes that bind to amyloid-β plaques could provide important diagnostic information on amyloid-β plaque burden using Single Photon Emission Computed Tomography (SPECT). Tridentate ligands with a stilbene functional group were used to form complexes with the fac-[M(I)(CO)3](+) (M = Re or (99m)Tc) core. The rhenium carbonyl complexes with tridentate co-ligands that included a stilbene functional group and a dimethylamino substituent bound to amyloid-β present in human frontal cortex brain tissue from subjects with Alzheimer's disease. This chemistry was extended to make the analogous [(99m)Tc(I)(CO)3](+) complexes and the complexes were sufficiently stable in human serum. Whilst the lipophilicity (log D7.4) of the technetium complexes appeared ideally suited for penetration of the blood-brain barrier, preliminary biodistribution studies in an AD mouse model (APP/PS1) revealed relatively low brain uptake (0.24% ID g(-1) at 2 min post injection).

[1]  David J Hayne,et al.  Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease. , 2014, Chemical Society reviews.

[2]  Robert B. Innis,et al.  Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Blood–Brain Barrier , 2013, Molecular pharmaceutics.

[3]  Boli Liu,et al.  Novel cyclopentadienyl tricarbonyl complexes of (99m)Tc mimicking chalcone as potential single-photon emission computed tomography imaging probes for β-amyloid plaques in brain. , 2013, Journal of medicinal chemistry.

[4]  James L. Hickey,et al.  Diagnostic imaging of Alzheimer's disease with copper and technetium complexes , 2012 .

[5]  Lucie Yang,et al.  Brain amyloid imaging--FDA approval of florbetapir F18 injection. , 2012, The New England journal of medicine.

[6]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[7]  S. Hitchcock,et al.  Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.

[8]  T. Matsuo,et al.  Synthesis of Rhenium(I) Tricarbonyl Complexes with Carbohydrate-Pendant Tridentate Ligands and Their Cellular Uptake , 2012 .

[9]  Victor L. Villemagne,et al.  Brain Amyloid Imaging , 2011, The Journal of Nuclear Medicine.

[10]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[11]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[12]  G. Gasser,et al.  Sequential insertion of three different organometallics into a versatile building block containing a PNA backbone. , 2010, Dalton transactions.

[13]  D. Skovronsky,et al.  18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. , 2010, Journal of medicinal chemistry.

[14]  Jerry Yang,et al.  Rational Design of Amyloid Binding Agents Based on the Molecular Rotor Motif , 2010, ChemMedChem.

[15]  Tyler E. Benedum,et al.  Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain , 2009, Journal of Nuclear Medicine.

[16]  N. Buurma,et al.  Rhenium complexes of chromophore-appended dipicolylamine ligands: syntheses, spectroscopic properties, DNA binding and X-ray crystal structure , 2008 .

[17]  J. Valliant,et al.  Expedient multi-step synthesis of organometallic complexes of Tc and Re in high effective specific activity. A new platform for the production of molecular imaging and therapy agents. , 2008, Inorganic chemistry.

[18]  C. Raptopoulou,et al.  Preparation and characterization of technetium and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive diagnostic radiopharmaceuticals. In vitro and in vivo studies. , 2008, European journal of medicinal chemistry.

[19]  A. Terzis,et al.  Convenient route leading to neutral fac-M(CO)3(NNO) complexes (M = Re, 99mTc) coupled to amine pharmacophores. , 2008, Inorganic chemistry.

[20]  Lianfeng Zhang,et al.  Synthesis and biological evaluation of 99mTc, Re-monoamine-monoamide conjugated to 2-(4-aminophenyl)benzothiazole as potential probes for beta-amyloid plaques in the brain. , 2008, Bioorganic & medicinal chemistry letters.

[21]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[22]  Tyler E. Benedum,et al.  Novel Styrylpyridines as Probes for SPECT Imaging of Amyloid Plaques , 2007 .

[23]  H. Kung,et al.  18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. , 2007, Nuclear medicine and biology.

[24]  H. Kung,et al.  F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. , 2005, Nuclear medicine and biology.

[25]  H. Kung,et al.  F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. , 2005, Journal of medicinal chemistry.

[26]  R. Schibli,et al.  Comparative studies of substitution reactions of rhenium(I) dicarbonyl-nitrosyl and tricarbonyl complexes in aqueous media. , 2005, Inorganic chemistry.

[27]  J. Zubieta,et al.  A new tricarbonylrhenium(I) compound incorporating the tridentate ligand N,N-bispicolyl-2-ethanolamine. , 2005, Acta Crystallographica Section C: Crystal Structure Communications.

[28]  R. Schibli,et al.  Functionalization of glucose at position C-3 for transition metal coordination: organo-rhenium complexes with carbohydrate skeletons. , 2005, Bioconjugate chemistry.

[29]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[30]  R. Bendayan,et al.  Functional Expression and Localization of P-glycoprotein in the Central Nervous System: Relevance to the Pathogenesis and Treatment of Neurological Disorders , 2004, Pharmaceutical Research.

[31]  J. Zubieta,et al.  Bifunctional chelates with aliphatic amine donors for labeling of biomolecules with the {Tc(CO)3}+ and {Re(CO)3}+ cores: the crystal and molecular structure of [Re(CO)3{(H2NCH2CH2)2 N(CH2)4CO2Me}]Br ☆ , 2004 .

[32]  Alan A. Wilson,et al.  11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. , 2003, Nuclear medicine and biology.

[33]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[34]  J. Zubieta,et al.  Bifunctional single amino acid chelates for labeling of biomolecules with the {Tc(CO)3}+ and {Re(CO)3}+ cores. Crystal and molecular structures of [ReBr(CO)3(H2NCH2 C5H4N)], [Re(CO)3{(C5H4 NCH2)2NH}]Br, , 2002 .

[35]  M. Kung,et al.  Novel stilbenes as probes for amyloid plaques. , 2001, Journal of the American Chemical Society.

[36]  R. Schibli,et al.  Synthesis and properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of [(99m)Tc(OH(2))3(CO)3]+. , 2001, Journal of the American Chemical Society.

[37]  Roger Schibli,et al.  Basic aqueous chemistry of [M(OH2)3(CO)3]+ (M=Re, Tc) directed towards radiopharmaceutical application , 1999 .

[38]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[39]  R. Schibli,et al.  Reactions with the technetium and rhenium carbonyl complexes (NEt4)2[MX3(CO)3]. Synthesis and structure of [Tc(CN-But)3(CO)3](NO3) and (NEt4)[Tc2(μ-SCH2CH2OH)3(CO)6] , 1996 .

[40]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[41]  P. van der Sluis,et al.  BYPASS: an effective method for the refinement of crystal structures containing disordered solvent regions , 1990 .

[42]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Raichle,et al.  Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.